The Race of CAR Therapies: CAR-NK Cells for Fighting B-Cell Hematological Cancers
Acute lymphoblastic leukemia (ALL) and Chronic lymphocytic leukemia (CLL) are the most common leukemias in children and elderly people, respectively. Standard therapies, such as chemotherapy, are only effective in 40% of ALL adult patients with a five-year survival rate and therefore new alternative...
Saved in:
Main Authors: | Lara Herrera, Silvia Santos, Miguel Angel Vesga, Tomas Carrascosa, Juan Carlos Garcia-Ruiz, Antonio Pérez-Martínez, Manel Juan, Cristina Eguizabal |
---|---|
Format: | article |
Language: | EN |
Published: |
MDPI AG
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/4ba5c4420bbb41e9b71bdae59fe70e56 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Horses for Courses in the Era of CARs: Advancing CAR T and CAR NK Cell Therapies
by: Sergey Kulemzin, et al.
Published: (2021) -
Current Perspectives on “Off-The-Shelf” Allogeneic NK and CAR-NK Cell Therapies
by: Erica L. Heipertz, et al.
Published: (2021) -
Cellular immunotherapy for hematological malignancy: recent progress and future perspectives
by: Zhengli Xu, et al.
Published: (2021) -
Cell Therapy for Colorectal Cancer: The Promise of Chimeric Antigen Receptor (CAR)-T Cells
by: Cristina Aparicio, et al.
Published: (2021) -
The Biological Role and Therapeutic Potential of NK Cells in Hematological and Solid Tumors
by: Rodion A. Velichinskii, et al.
Published: (2021)